<DOC>
	<DOCNO>NCT02869438</DOCNO>
	<brief_summary>The purpose study investigate onset maintenance effect benralizumab lung function , blood eosinophil , asthma control metric quality life 12-week treatment patient uncontrolled , severe asthma eosinophilic inflammation . A subset patient take part body plethysmography substudy investigate effect lung function .</brief_summary>
	<brief_title>A Study Evaluate Onset Effect Time Course Change Lung Function With Benralizumab Severe , Uncontrolled Asthma Patients With Eosinophilic Inflammation</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<criteria>Inclusion criterion 1 . Written inform consent study participation must obtain prior study related procedure perform accord international guideline and/or applicable European Union ( EU ) guideline . 2 . Female male age 18 75 year inclusively time Visit 1 3 . Documented current treatment ICS LABA least 30 day prior Visit 1 . The ICS LABA part combination product give separate inhaler . The ICS dose must great equal 500 μg/day fluticasone propionate dry powder formulation equivalent daily . Additional asthma controller medication , eg , oral corticosteroid , longacting antimuscarinics ( LAMAs ) , LTRAs , theophylline etc . allow use least 30 day prior Visit 1 4 . History least 2 asthma exacerbation require treatment systemic corticosteroid ( intramuscular ( IM ) , intravenous ( IV ) , oral ) 12 month prior Visit 1 . For patient receive corticosteroid maintenance therapy , corticosteroid treatment exacerbation define temporary increase maintenance dose . 5 . Prebronchodilator ( preBD ) FEV1 &lt; 80 % predict Visit 2 Visit 3 6 . ACQ6 score ≥1.5 Visit 1 7 . Evidence asthma document airway reversibility ( FEV1 ≥12 % 200 ml ) demonstrate Visit 1 , Visit 2 Visit 3 . For patient enter body plethysmography substudy , reversibility must demonstrate Visit 1 Visit 2 8 . Peripheral blood eosinophil count ≥300 cells/μL assess central lab Visit 1 9 . Women childbearing potential ( WOCBP ) must use effective form birth control confirm Investigator . WOCBP must also negative serum pregnancy test result Visit 1 . Women childbearing potential defined woman either permanently sterilize ( hysterectomy , bilateral oophorectomy , bilateral salpingectomy ) , postmenopausal . Women consider postmenopausal amenorrheic 12 month prior plan date randomization without alternative medical cause . The follow agespecific requirement apply : Women &lt; 50 year old consider postmenopausal amenorrheic 12 month follow cessation exogenous hormonal treatment follicle stimulate hormone ( FSH ) level postmenopausal range . Women ≥50 year old consider postmenopausal amenorrheic 12 month follow cessation exogenous hormonal treatment . 10 . All male patient sexually active must agree use double barrier method contraception ( condom spermicide ) first dose IP 16 week last dose 11 . Weight ≥40 kg Additional inclusion criterion applicable Body Plethysmography substudy 1.Residual volume ≥125 % predict Visit 3 . Inclusion criterion randomization visit 1 . At least 1 follow within 7 day prior randomization : Daytime nighttime asthma symptom 2 day ; Rescue SABA use 2 day ; Nighttime awakening due asthma least 1 night 7day period 2 . ACQ &gt; 0.75 Visit 4 prior randomization . 3 . A negative urine pregnancy test WOCBP prior administration IP Exclusion criteria 1 . Clinically important pulmonary disease asthma ( eg , active lung infection , COPD , bronchiectasis , pulmonary fibrosis , cystic fibrosis , hypoventilation syndrome associate obesity , lung cancer , alpha 1 antitrypsin deficiency , primary ciliary dyskinesia ) ever diagnose pulmonary systemic disease , asthma , associate elevated peripheral eosinophil count ( eg , allergic bronchopulmonary aspergillosis/mycosis , ChurgStrauss syndrome , hypereosinophilic syndrome ) 2 . Lifethreatening asthma define episode require intubation associate hypercapnia , respiratory arrest , hypoxic seizure , asthma relate syncopal episode within 12 month prior Visit 1 . 3 . Acute upper low respiratory infection require antibiotic antiviral medication within 30 day prior date informed consent obtain screening/runin period 4 . An upper respiratory tract infection asthma exacerbation require treatment systemic corticosteroid increase regular maintenance dose OCS screening/runin period prior randomization Visit 4 5 . Any disorder , include , limited , cardiovascular , gastrointestinal , hepatic , renal , neurological , musculoskeletal , infectious , endocrine , metabolic , haematological , psychiatric , major physical impairment stable opinion Investigator could : Affect safety patient throughout study Influence finding study interpretation Impede patient 's ability complete entire duration study 6 . Known history allergy reaction component investigational product formulation 7 . History anaphylaxis biologic therapy 8 . History GuillainBarré syndrome 9 . A helminth parasitic infection diagnose within 24 week prior date informed consent obtain treat , fail respond standard care therapy 10 . Any clinically significant abnormal finding physical examination , vital sign , hematology , clinical chemistry , urinalysis screening period , opinion Investigator , may put patient risk his/her participation study , may influence result study , patient 's ability complete entire duration study 11 . Any clinically significant cardiac disease electrocardiogram ( ECG ) abnormality obtain screening/runin period , opinion Investigator may put patient risk interfere study assessment 12 . History alcohol drug abuse within 12 month prior date informed consent obtain 13 . Positive hepatitis B surface antigen , hepatitis C virus antibody serology , positive medical history hepatitis B C. Patients history hepatitis B vaccination without history hepatitis B allow enroll 14 . A history know immunodeficiency disorder include positive human immunodeficiency virus ( HIV ) test 15 . Current smoker former smoker smoke history ≥10 pack year . A former smoker define patient quit smoking least 6 month prior Visit 1 16 . Current malignancy , history malignancy , except : Patients basal cell carcinoma , localize squamous cell carcinoma skin situ carcinoma cervix eligible provide patient remission curative therapy complete least 12 month prior date informed consent obtain . Patients malignancy eligible provide patient remission curative therapy complete least 5 year prior date informed consent obtain . 17 . Use immunosuppressive medication ( include limit : oral corticosteroid [ reason asthma ] , methotrexate , troleandomycin , cyclosporine , azathioprine , intramuscular longacting depot corticosteroid experimental antiinflammatory therapy ) within 3 month prior date inform consent 18 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) level ≥1.5 time upper limit normal ( ULN ) confirm screening period 19 . Receipt immunoglobulin blood product within 30 day prior date informed consent obtain 20 . Receipt market ( eg , omalizumab , mepolizumab etc . ) investigational biologic within 4 month 5 halflives prior date inform consent obtain , whichever longer 21 . Receipt live attenuate vaccine 30 day prior date randomization 22 . Receipt investigational medication within 30 day 5 halflives prior randomization , whichever longer 23 . Previously receive benralizumab ( MEDI563 ) 24 . Planned surgical procedure conduct study 25 . Currently breastfeed lactate woman 26 . Previous randomization present study 27 . Concurrent enrolment another interventional postauthorization safety study ( PASS ) . 28 . AstraZeneca staff involve planning and/or conduct study 29 . Employees study center individual involve conduct study immediate family member individual Exclusion criterion randomization Visit 4 1 . Greater than/equal 20 % change mean Pre BD FEV1 value randomization Visit 4 mean pre BD FEV1 calculate pre BD FEV1 record Visit 2 Visit 3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Asthma , Bronchial Diseases , Respiratory Tract Diseases , Lung Diseases , Obstructive Lung Diseases</keyword>
</DOC>